RFL News and Press, Rafael Holdings Inc. Class B From 01/13/20

NEWARK, N.J. , Jan. 13, 2020 /PRNewswire/ -- The Barer Institute, a collaborative cancer drug development initiative of Rafael Holdings, Inc. , (NYSE: RFL), today announced the slate of highly regarded scientific and business leaders that will serve as its founding Board of Director...

Cranbury, NJ, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism -based therapeutics, today announced that Sanjeev Luther, President and Chief Executive Officer, will p...

NEWARK, N.J. , Dec. 19, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), has launched an initiative to identify and develop or in-license promising pre-clinical compounds targeting the unique cellular metabolism of cancers with high levels of unmet needs.  The Rafael Holdi...

The following slide deck was published by Rafael Holdings, Inc. in conjunction with this Read more ...

Rafael Holdings (NYSE: RFL ): Q1 GAAP EPS of -$0.10. More news on: Rafael Holdings, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NEWARK, N.J. , Dec. 9, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.10 for the fiscal quarter ended October 31, 2019 . Recent Operational Highlights Rafael Holdings became a New York Stock E...

NEWARK, N.J. , Dec. 5, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), announced that it will present at the 12th Annual LD Micro Main Event investor conference. David Polinsky , Rafael's Chief Financial Officer, and Ari Landon , Director of Rafael Holdings' cancer the...

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Ariela Noy, M.D., hematologic oncologist at Memorial Sloan Kett...

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Co-Chief Medical Officer, Timothy Pardee, M.D., Ph.D., will lead...

Cranbury, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 2 clinical trial of CPI-613® (devi...